Dr Reddy’s – Continuing its healthy growth across the globe
Posted by : Sheen Hitaishi | Thu Aug 03 2023
[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_spacing=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”.vc_custom_1691068756722{margin-right: 16px !important;margin-left: 16px !important;border-right-width: 10px !important;border-left-width: 10px !important;}”]Dr Reddy’s Laboratories is a leading Indian pharmaceutical company and the fourth largest in terms of market capitalisation. It was incorporated in the year 1984 in Hyderabad by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. In 1986, the company shares were listed on the Bombay Stock Exchange.
It has three key verticals, PSAI (Pharmaceutical Services and Active Ingredients), GG (Global Generics) and Proprietary Products. The Company offers a portfolio of products and services, including APIs (Active Pharmaceutical Ingredients), generics, biosimilars and differentiated formulations.
Growth momentum continues in Q1FY24
In the recently announced Q1FY24 results, the company recorded its highest revenue and net profits in the last five quarters, indicating healthy growth.
Commenting on the Q1FY24 results, Co-Chairman & MD, G V Prasad said: “We delivered strong sales growth and witnessed robust margin expansion in Q1FY24 driven by market share gains & new product momentum in our US generics business and superior performance in Russia. We are on track in executing our strategy, delivering growth while continuing to invest in future growth drivers and innovation to create sustainable value.”
The Q1FY24 results continue the growth momentum from the past few quarters. On analyzing the revenues and net profits for the last five financial years, the company ended FY23 on a strong note with its highest-ever revenues and net profits.
The company has consistently seen its revenues grow for the past four years, with FY23 revenues reaching Rs 25,725.2 crore. Notably, in FY23, the profits also grew sharply, doubling from the previous year.
The growth in Q1FY24 came from contributions from each of the business units. In the GG (Global Generics) vertical, growth was driven by North America, Emerging markets, and Europe.
The growth in North America was primarily due to new product launches, continued momentum in existing products, favorable forex rate movements, partly offset by price erosion. Other factors aiding this geography include the launch of six new products in the US and two in Canada.
Revenue from Russia for Q1FY24 stood at Rs. 5.6 billion, showing a YoY growth of 75% and a QoQ growth of 9%. The growth was driven by an uptick in the base business, price increases, and biosimilars. In other CIS countries and Romania, revenue for the year reached Rs. 2.0 billion, marking a YoY growth of 2% but experiencing a QoQ decline of 14%. The YoY growth was primarily due to price increases on certain products, but it was offset by a decline in base business volumes.
The growth was also supported by expanding margins. In Q1FY24, the operating profits stood at Rs. 2,062.1 crore with a margin of 30.5%, higher than the previous quarter’s margin of 24.3%. The improvement in gross margin was primarily driven by a favorable product mix and higher manufacturing leverage.
Evaluating key financial metrics, such as the Return on Capital Employed (ROCE) and Return on Equity (ROE), gives a picture of the company’s financial prudence. Both these metrics have also seen improvement in fiscal year 2023, with ROCE rising to 26.0% from 15.4% in fiscal year 2022. Similarly, the ROE rose to 19.4% in fiscal year 2023 from 11.4% in fiscal year 2022.
Favourable triggers for this financial year could play out to its advantage
Dr. Reddy’s recent performance has been driven by new launches like gRevlimid and windfall from product shortages in the US, as bankrupt companies have withdrawn their products. Profits from these products have improved the net cash balance to Rs 50 billion at the end of Q1FY24, which the company intends to pursue for R&D as well as acquisitions in India and overseas.
As of 30th June 2023, there are cumulatively 85 generic filings pending for approval with the USFDA (82 ANDAs and 3 NDAs under 505(b)(2) route). Out of the pending 85 ANDAs, 43 are Para IVs, and 17 have ‘First to File’ status. As the approvals for these come in, the company’s portfolio is bound to get wider.
Exceptional income from litigation settlement to boost earnings marginally in FY24: The company has received one-time settlement income of CAD 9 million (Rs 56 crore) from Janssen Group in relation to a litigation around ANDS for a generic version of Zytiga (Abiraterone).
The management also plans to focus on growth in India and expects to double its sales in China in the next three years from the current $180 million. The management has guided for gross margins between 56-59% for FY24.
Considering that these factors play out favorably over this financial year, we can expect an upside of 26% from the current levels (5600) by the end of FY24.
ABOUT THE AUTHOR
Ketan Sonalkar (SEBI Rgn No INA000011255 )
Ketan Sonalkar is a certified SEBI registered investment advisor and head of research at Univest. He is one of the finest financial trainers, with a track record of having trained more than 2000 people in offline and online models. He serves as a consultant advisor to leading fintech and financial data firms. He has over 15 years of working experience in the finance field. He runs Advisory Services for Direct Equities and Personal Finance Transformation.
Note – This channel is for educational and training purpose only & any stock mentioned here should not be taken as a tip/recommendation/advice
You may also like: Weekly update
[/vc_column_text][/vc_column][/vc_row]
Related Posts